No Data
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $7
Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $11
Market-Moving News for February 19th
Express News | Chemomab Therapeutics Shares Are Trading Higher After the Company Announced the Completion of Its End-of-phase 2 FDA Meeting and Alignment on a Single Phase 3 Registration Study for Nebokitug
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns With FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
HOHAAH : The volume is gone. Everyone has left